72 results
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
.
Stockholder Meetings
Our bylaws provide that a special meeting of stockholders may be called only by our chairperson of the board, chief executive officer
424B5
2i6f73iqbd6e cm
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
v1j2qgscc2bfob1i7
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
vak93eqqihaqe3mek
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
quw0qj50e
11 Mar 21
Prospectus supplement for primary offering
9:19am
424B4
rhzzh 8vjhcgf
17 Feb 21
Prospectus supplement with pricing info
7:14am
8-K
EX-10.8
f7d4g3p5ad
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
uba13ph
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-3.3
63nedk
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
n3f x4f7s9cmj8g9i
3 Nov 20
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
6:06am
8-K
EX-99.1
qy6c4a4
3 Nov 20
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
6:06am
425
881 b9n203lp
3 Nov 20
Business combination disclosure
6:04am